2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of thePreclinical Assets Market?

The upward trend in drug discovery is predicted to boost the expansion of the preclinical asset market in the future. Drug discovery involves the identification of chemical substances with potential medicinal properties, marking the birth of new possible medications. Preclinical assets serve a crucial function in this procedure, contributing crucial data and validation to assist in the selection of molecules for clinical development. For instance, as reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA) – a Belgium-based entity advocating for the pharmaceutical sector, there was a significant increase in the European pharmaceutical industry’s production in June 2023, escalating from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the growth of the preclinical assets market is being propelled by the escalating drug discovery.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

How Will the Growth Rate of thePreclinical Assets Market Impact Industry Trends by 2034?

In recent times, the size of the preclinical assets market has witnessed robust growth. It is projected to intensify from $5.87 billion in 2024 to $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. The surge during the historical period may be credited to the demands for drug development, advancements in biotechnology, regulatory prerequisites, the expansion of research funding, and collaborative research endeavors.

The market for preclinical assets is anticipated to experience a robust growth in the coming years. With a compound annual growth rate (CAGR) of 9.8%, it is predicted to surge to $9.3 billion by 2029. Factors driving this growth during the forecast period include the rising prominence of precision medicine and personalized therapies, the integration of artificial intelligence and machine learning, expansion of biobanking, heightened focus on rare diseases, and governmental initiatives and funding. Moreover, emerging trends within the forecast period such as advanced imaging techniques, 3D organoid models, integration of multi-omics, improved predictive models, automation, and high throughput screening will further stimulate the market growth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

Which Upcoming Market Trends and Innovations Are Set to Influence the Preclinical Assets Market’s Path Forward?

The growing trend of product innovations is making substantial headway in the preclinical assets market, as primary companies in this sector focus on the introduction of new products and solutions for solidifying their market standing and for securing a competitive edge. For instance, in April 2022, Charles River Laboratories International, a pharmaceutical company based in the US with numerous preclinical and clinical laboratories, alongside Valo Health Inc., a US-based tech firm aiming to revolutionize drug discovery, together initiated Logica, an AI-powered drug solution. This solution effectively transforms clients’ biological findings into optimized preclinical assets. Logica utilizes the superior preclinical knowledge of Charles River and the AI-enabled Opal Computational Platform of Valo to offer clients a unique drug discovery method through a single, integrated package that seamlessly turns targets into candidate nominations. By associating with Valo, Charles River merges its lab expertise with molecular design technology, thereby wreaking a significant transformation in the industry. This collaboration ensures the delivery of highly suitable leads and candidates to clients while tying client expenses to value generation.

Who Are the Dominant Market Players Pushing the Boundaries of thePreclinical Assets Market?

Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

#thebusinessresearchcompany #marketresearch #marketintelligence

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

What Regions Are Dominating the Preclinical Assets Market Growth?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Preclinical Assets Maret 2025, By The Business Research Company:

Asset-Backed Securities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/asset-backed-securities-global-market-report

Preclinical Imaging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Defense IT Spending Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/defense-it-spending-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: